The P-I/II (CHORD) dose escalation & expansion study assesses DB-OTO’s safety, tolerability & efficacy to treat otoferlin mutated hearing loss. The trial is currently recruiting children in the US, UK & Spain
The therapy in 1st patient (16mos.) showed an improvement of avg. 84 dB from baseline with 1 frequency measure achieving 10 dB in hearing level per PTA & avg. 80 dB improvement from baseline at all tested frequencies. ABR responses achieved a 45 dB frequency at the 24wks.
The 2nd patient (4yrs.) had an improvement of avg. 19 dB from baseline with 1 frequency measure achieving 80 dB in hearing level per PTA & avg. 16 dB improvement from baseline at all tested frequencies. ABR responses achieved a 75 dB frequency at 6wks.
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron and Mammoth Collaborate for CRISPR Gene Editing Therapies Against Multiple Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
